slide1
Download
Skip this Video
Download Presentation
The Fifty Year Revolution in Global Public Health

Loading in 2 Seconds...

play fullscreen
1 / 28

The Fifty Year Revolution in Global Public Health - PowerPoint PPT Presentation


  • 103 Views
  • Uploaded on

The Fifty Year Revolution in Global Public Health. Sir Gustav Nossal Department of Pathology The University of Melbourne Victoria, Australia. 50th Anniversary Lecture, The Medical Foundation, The University of Sydney 30 July 2008.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'The Fifty Year Revolution in Global Public Health' - seymour


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1
The Fifty Year Revolution in

Global Public Health

Sir Gustav Nossal

Department of Pathology

The University of Melbourne

Victoria, Australia

50th Anniversary Lecture, The Medical Foundation,

The University of Sydney

30 July 2008

slide2
Major Currents are Sweeping Through the Development Aid Field
  • In July 2005, the G8 group of nations committed themselves to a new moral imperative: get rid of extreme poverty in the world; double aid to Africa.
  • With the exception of a few countries, academic and other leaders in developing countries are now ready for true partnerships.
  • Civil society must hold politicians to their promises. G8 already falling behind.
slide3
The Moral Imperative of Poverty Reduction

“Our policy is directed not against any country or doctrine but against hunger, poverty, desperation and chaos. There’s no doubt in my mind that the whole world hangs in the balance.”

U.S. Secretary of State George C. Marshall, 1948, commenting on the Marshall Plan for the reconstruction of Europe which cost USA 4% of GDP for some years (today’s equivalent $500 billion/year).

“Make Poverty History”

Bono and Bob Geldof, July 2005

slide4
The Need is for a New Global Marshall Plan
  • THE WORLD CAN EASILY AFFORD 0.7% GDP FOR AID

2008 World GDP : $60.1 Trillion, Growth 5% p.a.

2008 E.U. GDP : $18.5 Trillion

2008 U.S.A. GDP : $14.2 Trillion

2008 Arab League GDP : $1.8 Trillion

  • 0.7% of GDP for “richer” countries would be $280 billion. Current ODA is $105 billion. OECD average is 0.3% of GDP. Norway (0.9%), Sweden (0.9%), Luxembourg (0.9%), Netherlands (0.8%) and Denmark (0.8%) only countries above 0.7%. U.S.A. 0.2%, Australia 0.3% – plans to go to 0.5% by 2015.
  • DISTRIBUTION NEEDS QUESTIONING: SUB-SAHARAN AFRICA 20%, IRAQ 15%.
slide5
The Moral Imperative of Health
  • Important from a humanitarian point of view.
  • Important from an educational point of view.
  • Important from an economic point of view.
  • A virtuous circle unites health, education and economic growth.
  • 41 life-saving interventions would cost $40 per person per year and save 8 million lives per year.
  • Economic benefit would be $6 for every dollar spent.
slide6
The Moral Imperative of Health (continued)

“There is absolutely no excuse for us to live on a planet where, at 10 cents per $100, millions of lives could be saved every year. It’s hard to understand why we kill people, but absolutely unthinkable how we let millions of people die when we stand by without understanding what is in our own interest and moral obligation.”

Jeffrey D. Sachs, Earth Institute, Columbia University, 2003.

slide7
The Moral Imperative of Communicable Diseases

Within health, the aid priorities should be:

  • Infectious Diseases
  • Nutrition, especially micronutrients
  • Antenatal and Obstetric Care
  • Birth spacing
  • Diabetes
slide8
Health Progress is Possible (1)
  • Deaths in children under 5 a record low in 2006, 9.7 million versus 13 million in 1990.
  • Sub-Saharan Africa 4.8 million, South Asia 3.1 million.
  • Among preventable deaths:

Pneumonia 1.8 million

Diarrhoea 1.6 million

Malaria 780 thousand

Measles 390 thousand

AIDS 290 thousand

slide9
Health Progress is Possible (2)
  • Some Massive New Programmes Since2000
  • Global Fund to fight AIDS, TB and malaria (2002)
  • President’s Emergency Plan for AIDS relief (2004)
  • Gates Foundation Programs (Corpus $70 billion) (2000)
  • Other Programmes are Getting Traction
  • Polio Eradication
  • Stop TB Partnership
  • Malaria Control
  • Iodine fortification
  • Onchocerciasis Control Programme
  • Elimination of Lymphatic Filariasis
  • Eye Health (cataracts, trachoma)
slide10
Global Fund to Fight AIDS, TB and Malaria(As of June 2008)
  • In first 6 years of programme, U.S. $10.7 billion pledged to 136 countries.
  • 1.75 million patients on HAART.
  • 46 million people given HIV testing/counselling.
  • 3.9 million people on TB chemotherapy.
  • 59 million insecticide-impregnated bednets distributed.
  • 60 million malaria treatments given.
  • 7.6 million community health workers trained.
slide11
President’s Emergency Plan for AIDS Relief(As of June 2008)
  • Budget is $6 billion for 2008 targetted to 15 focus countries.
  • Funds also provided to Global Fund and malaria control.
  • 3.5 million people in 2008 treated with HAART combining both funds.
  • Goal for G8 and UN: By 2010, 100% coverage of AIDS patients.
  • 12.7 million pregnancies surveyed for prevention of mother to child transmission, ARV prophylaxis for 1 million.
slide12
Polio Eradication is Still Problematic
  • 4 Polio endemic countries:
  • (Cases to date 2008)

Nigeria (318)

India (275)

Pakistan (14) Afghanistan (8)

  • 6 Importation countries remain of 27 re-infected.
  • Somalia now polio free; last case March 25, 2007.
  • “Finishing the job of polio eradication is our best buy. It’s WHO’s top operational priority. We must do it”

Margaret Chan,

D-G, WHO

May 2008

slide13
Stop TB Partnership (2006)
  • 2 billion people infected with TB, 8.8 million new active cases per year and 1.6 million deaths per year.
  • DOTS the cornerstone. Including earlier DOTS programme, 22 million people treated since 1995 in 183 countries. Success rates 70-80%.
  • MDR: Multidrug resistance = resistance to cheaper, first-line drugs.
  • XDR: Extreme drug resistance = resistance to any fluoroquinolone and to at least one of three injectable second-line drugs. Specially targetted pilot programmes addressing drug sensitivity surveillance.
  • HIV-positive people are 50 times more likely to develop active TB in their lifetime than HIV-negative people.
slide14
Malaria
  • At least 300 million attacks per year.
  • At least 1 million deaths.
  • Resistance to drugs; Anopheles resistance to insecticides.
  • Insecticide – impregnated bed nets (pyrethroids) at $5 each reduce malaria mortality >50% and all causes mortality 20%.
  • New drugs: “Medicines for Malaria Venture”. Public-private partnership 1999. Includes 39 R&D partners. 11 drugs in clinical trials; 5 are artemisinine derivatives.
slide15
Onchocerciasis Control Programme
  • OCP ran from 1974 to 2002 to protect 30 million people in 11 countries of West Africa from river blindness.
  • Progressed from larviciding (of Simulium damnosum) to spraying plus ivermectin to ivermectin alone.
  • Huge success, river blindness virtually eradicated, 600,000 cases of river blindness prevented, 18 million children born spared the risk, 25 million hectares of land rendered safe for cultivation and resettlement.
slide16
Global Alliance to Eliminate Lymphatic Filariasis
  • More than 1 billion people in 80 countries live at risk of lymphatic filariasis (elephantiasis), a parasitic infection spread by mosquitoes. There are 120 million already infected and 40 million significantly disfigured.
  • GlaxoSmith Kline (albendazole) and Merck (ivermectin) have pledged all the drug doses needed - valued at over $1 billion.
  • Community-wide drug treatment once per year also dramatically and persistently reduces hookworm and roundworm infections.
  • So far, some 400 million people have been reached.
slide17
Progress of the GAVI Alliance 2000–2007
  • 36.8 million extra children received standard vaccines.
  • 176 million children received any or all of hepatitis B, Hib and yellow fever vaccines.
  • Measles deaths reduced by 60% (aiming for 90% by 2010).
  • Estimated 2.9 million deaths prevented.
  • Budget rising progressively to $1.5 billion/year.
  • Bill Gates re his $1.5 billion donation: “My best investment ever”.
slide18
GAVI Alliance Challenges
  • 26.3 million children each year still not immunised.
  • Still 2.5 million vaccine-preventable deaths each year.
  • Need $10 to 15 billion extra over next ten years.
slide19
International Finance Facility–Immunisation
  • Bonds issued through the international capital markets guaranteeing large, immediately available sums and are redeemed via legally binding pledges from governments of donor countries.
  • On 14 November, 2006 IFFIm placed US$1 billion 5 year bonds at 5.2%. Investors included central banks, major funds but also “Mums and Dads”.
  • Over the next 10 years, IFFIm plans to raise at least $5.5 billion for the GAVI Alliance.
  • Donor countries are the U.K., France, Italy, Spain, Norway, Sweden, South Africa and Brazil.
slide20
Advanced Market Commitments (AMCS) for Vaccines
  • A new mechanism for development and subsidised purchase of priority vaccines, including ones not yet invented.
  • On 9 February 2007, Streptococcus pneumoniae was chosen as the first target as it kills 1.6 million people annually.
  • US$ 1.5 billion pledged with Italy, the U.K. and Canada contributing the lion’s share.
  • AMCS will fund research, support development, provide funds for a sustainable supply and negotiate a reasonable price.
slide21
The Huge Success of Carbohydrate-Protein Conjugate Vaccines Against Encapsulated Bacteria
  • Virtual elimination of Hib and N. meningitidis C meningitis in industrialized countries. Progress in Third World.
  • 7-valent pneumococcal conjugate is excellent; need more serotypes; a common protein vaccine via genome mining would be welcome. So would one for N. meningitidis B and non-typable Haemophilus.
  • An exciting third world initiative on epidemic meningitis in Africa.
slide22
Progress with Specific Vaccines: African Meningitis
  • WHO–PATH Meningitis Vaccine Initiative on track using monovalent Mening A conjugate.
  • Production is by Serum Institute of India, Pune, in association with 2 CRO’s for technology transfer.
  • 8 June 2007: 600 12-23 month old children in Mali and The Gambia make 20 times more antibody than with unconjugated vaccine.
  • Dell Foundation to fund demonstration study: Single dose all 1-29 year olds in Burkina Faso in 2009.
  • $400 million will be required to immunize 350 million people in 20 other countries.
slide23
Progress with Diarrhoeal Disease Vaccines Has Been Slower
  • Two rotavirus vaccines licensed but expensive. Hope for a cheaper product from the virus’s Australian discoverers.
  • Good vaccines exist against cholera and typhoid but are not being used sufficiently.
  • Pre-clinical work for shigellosis and enterotoxigenic E. coli is promising but clinical trials are lagging.
slide24
The Moral Imperative of Vaccines Which Prevent Viral Causes of Cancer
  • Increased use of hepatitis B vaccine through GAVI is heartening.
  • Some research progress towards a hepatitis C vaccine.
  • The human papilloma virus vaccine has been brilliantly successful.
  • For the second generation, more HPV genotypes will have to be included.
  • Plans for a Helicobacter pylori vaccine are on hold. Peptic ulcer disease and gastric cancer are very important.
slide25
Progress with the “Big 3” Vaccines –

Malaria

  • GSK sporozoite vaccine RTS, S with AS02D adjuvant shown to be safe and immunogenic in children and infants in Mozambique in Phase II trials.
  • Per cent efficacy and duration of protection remain problems with this vaccine.
  • Two studies of blood stage antigen AMA-1 are in Phase I clinical trial.
  • Steve Hoffman’s live, attenuated, mosquito salivary gland-derived vaccine (Sanaria) 90% effective in human volunteers for 4 years. Clinical trials are planned for late 2008.
slide26
Progress with “the Big 3” Vaccines – Tuberculosis
  • September 2007 Aeras Tuberculosis Vaccine Foundation receives $200 million from Gates Foundation. Jerry Sadoff
  • co-ordinates world effort.
  • Strategies include new BCG strains with genes for selected soluble antigens; as well as novel recombinant proteins with novel adjuvants; and also prime–boost regimens using adenovirus 35. Promising antigens include ESAT6, Ag85B, TB 10.4 and HSP90.
  • 6 Phase I studies have started or are about to start.
  • 2 Phase 3 trials hoped for by late 2010.
slide27
World effort in AIDS vaccine research now
  • US$ 800 million/year.
  • Strong attempts to achieve co-ordination and collaboration.

– Gates Collaboration for AIDS Vaccine Discovery

– N.I.H. Vaccine Research Center (intramural) and Centers for HIV/AIDS Vaccine Immunology (extramural)

– International Aids Vaccine Initiative

– Euro Vacc

– South African AIDS Vaccine Initiative

  • GHAVE: The global HIV/AIDS Vaccine enterprise (communication, knowledge management, policy development).

Progress with “the Big 3” Vaccines –

HIV / AIDS (1)

slide28
About 30 candidates in early clinical trials.
  • Merck on September 21, 2007, STOPPED its trial of adenovirus serotype 5 with gag, pol and nef expressed because of failure to prevent infection or to lower set point.
  • Only remaining candidate in efficacy trials:

– Sanofi-Pasteur canarypox vector with HIV inserts, boost with Vaxgen gp120 (16,000 persons in Thailand).

Progress with “the Big 3” Vaccines –

HIV / AIDS (2)

ad